Oriola-KD Corporation Stock Exchange Release 20 October 2016 at 8.30 a.m.
Oriola-KD Corporation's Interim Report for 1 January-30 September 2016
Financial performance July-September 2016
Financial performance January-September 2016
Outlook for 2016
Oriola-KD estimates its full-year net sales to remain at the 2015 level on constant currency basis. Adjusted operating profit is estimated to remain at 2015 level or to increase, on a constant currency basis. Full-year net sales in 2015 were EUR 1,626.3 million and adjusted operating profit was EUR 60.8 million.
President and CEO Eero Hautaniemi:
The third quarter invoicing in the Services business grew in line with the market, and profitability developed well in all operating countries. In the Consumer business our growth was weaker, but the sales mix continued to develop positively. We have established eight new pharmacies this year, and there are some to be opened in the fourth quarter as well. The profitability of the Consumer business declined due to the establishment costs.
We developed Oriola-KD according to our strategy; the acquisition of PharmaService complemented the Healthcare business with dose dispensing in Finland, and the acquisition of Farenta strengthened our Services offering to pharmacies and pharmaceutical companies.
Impact of new ESMA guidelines
New ESMA (European Securities and Markets Authority) guidelines on Alternative Performance Measures (APMs) are effective for the financial year 2016. Oriola-KD presents APMs to reflect the underlying business performance and to enhance comparability between financial periods. APMs should not be considered as a substitute for measures of performance in accordance with the IFRS. As of Q1 2016, Oriola-KD relabels the previously referenced "excluding non-recurring items" with "adjusted". Reporting segments' operating profit is reported excluding adjustment items. In addition Oriola-KD uses "invoicing" as the measure to describe the business volume.The reconciliation of the alternative performance measurements to performance measurements defined by IFRS are presented at the end of this interim report.
|EUR million||7-9||7-9 1)||%||1-9||1-9 1)||%||1-12|
|Adjusted EBITDA %||5.9||6.1||5.3||5.2||5.1|
|Adjusted operating profit 2)||17.0||17.5||-2.6||45.7||45.5||0.4||60.8|
|Adjusted operating profit %||4.3||4.6||3.8||3.8||3.7|
|Operating profit %||4.3||4.9||3.7||3.8||3.8|
|Profit for the period||12.3||13.8||-11.2||32.0||32.1||-0.3||44.5|
|Earnings per share, EUR||0.07||0.08||-9.2||0.18||0.18||-3.1||0.25|
|Net cash flow from operating activities||19.4||16.2||14.3||55.1||85.6|
|Gross investments, EUR million||73.5||13.2||20.4|
|Net interest-bearing debt||81.7||28.9||6.6|
|Net debt / 12-month EBITDA||0.9||0.3||0.1|
|Equity per share, EUR||1.06||0.96||1.07|
|Equity ratio, %||21.5||19.4||21.1|
|Return on equity (ROE), %||22.7||31.1||29.1|
|Return on capital employed (ROCE), %||18.3||20.4||19.9|
|Average number of shares, 1000 pcs 3)||181,374||176,204||177,502|
|Average number of personnel||2,497||2,320||2,327|
|Number of personnel at the end of the period||2,866||2,346||2,353|
| 1) Equity-related key figures restated as a result of correction of an error relating to previous financial periods. Correction was made in 2015 Financial Statements.|
2) Adjustment items are specified in table "Adjusting items included in Operating Profit"
3) Treasury shares held by the company not included
This stock exchange release is a summary of Oriola-KD Corporation's Interim Report January-September 2016. The complete report is attached to this release in pdf format and is also available on Oriola-KD's website at www.oriola-kd.com/investors.
Financial statements release
Oriola-KD Corporation will publish the financial statements release for 2016 on 10 February 2017.
President and CEO
tel. +358 (0)10 429 2109
tel. +358 (0)10 429 2112
NASDAQ OMX Helsinki Ltd
Orionintie 5, 02200 Espoo
Last updated on: 20/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.